DBV Technologies (NASDAQ:DBVT) Now Covered by StockNews.com

StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note published on Sunday. The brokerage issued a hold rating on the stock.

A number of other research analysts also recently issued reports on DBVT. HC Wainwright boosted their target price on shares of DBV Technologies from $25.00 to $35.00 and gave the company a “buy” rating in a research report on Thursday, October 24th. JMP Securities reissued a “market outperform” rating and set a $10.00 target price on shares of DBV Technologies in a research note on Friday, January 10th.

DBV Technologies Stock Down 2.6 %

Shares of DBVT opened at $4.15 on Friday. The company has a market cap of $85.38 million, a price-to-earnings ratio of -0.92 and a beta of 0.64. DBV Technologies has a twelve month low of $2.20 and a twelve month high of $9.49. The company has a 50 day moving average of $3.75 and a two-hundred day moving average of $3.87.

DBV Technologies (NASDAQ:DBVT) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($1.90) by $1.10. DBV Technologies had a negative net margin of 815.73% and a negative return on equity of 106.07%. The business had revenue of $1.07 million during the quarter, compared to the consensus estimate of $1.17 million. On average, sell-side analysts expect that DBV Technologies will post -7.05 EPS for the current year.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.